Terazosin
- Generic Name
- Terazosin
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25N5O4
- CAS Number
- 63590-64-7
- Unique Ingredient Identifier
- 8L5014XET7
- Background
Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension. Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate.
- Indication
Terazosin is indicated for use in treating symptomatic benign prostatic hyperplasia and hypertension.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Hypertension, Ureteral Calculus
Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related Symptoms
- Conditions
- Stent Related Symptoms
- Interventions
- First Posted Date
- 2025-05-13
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Penang Hospital, Malaysia
- Target Recruit Count
- 150
- Registration Number
- NCT06966804
- Locations
- 🇲🇾
Hospital Pulau Pinang, George Town, Pulau Pinang, Malaysia
Motor Function Efficacy of Pharmacological Treatments Targeting Energy Metabolism, in Parkinson's Patients
- Conditions
- Parkinson DiseaseMetabolic DiseaseGait AnalysisTherapy, Directly Observed
- Interventions
- First Posted Date
- 2023-05-11
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- I.R.C.C.S. Fondazione Santa Lucia
- Target Recruit Count
- 50
- Registration Number
- NCT05855577
Terazosin and Parkinson's Disease Extension Study
- Conditions
- Pre-motor Parkinson's DiseaseSymptomatic Parkinson DiseaseREM Sleep Behavior Disorder
- Interventions
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT05109364
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
Terazosin for Dementia with Lewy Bodies
- Conditions
- Dementia with Lewy Bodies
- Interventions
- Other: Placebo
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Qiang Zhang
- Target Recruit Count
- 40
- Registration Number
- NCT04760860
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
Target Engagement of Terazosin in Healthy Adults
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- University of Iowa
- Target Recruit Count
- 18
- Registration Number
- NCT04551040
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Terazosin Effect on Cardiac Changes in Early Parkinson's Disease
- Conditions
- REM Sleep Behavior DisorderPre-motor Parkinson's DiseaseSymptomatic Parkinson Disease
- Interventions
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT04386317
- Locations
- 🇺🇸
Michele L Lima Gregorio, Los Angeles, California, United States
A Pilot Study of Terazosin for Parkinson's Disease
- Conditions
- Parkinson Disease
- Interventions
- Drug: Placebo oral capsule
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2022-05-16
- Lead Sponsor
- Jordan Schultz
- Target Recruit Count
- 13
- Registration Number
- NCT03905811
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting
- Conditions
- Carotid Artery Stenosis
- Interventions
- Procedure: Carotid artery stenting
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- Capital Medical University
- Target Recruit Count
- 160
- Registration Number
- NCT03195673
- Locations
- 🇨🇳
The Luhe Teaching Hospital of the Capital Medical University, Beijing, Beijing, China
🇨🇳Beijing Anzhen Hospital, Beijing, Beijing, China
The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms
- Conditions
- Disorder of Urinary Stent
- Interventions
- First Posted Date
- 2012-02-09
- Last Posted Date
- 2015-03-02
- Lead Sponsor
- Urmia University of Medical Sciences
- Target Recruit Count
- 104
- Registration Number
- NCT01530243
- Locations
- 🇮🇷
Imam Khomeini Hospital, Urmia, Azerbaijan-gharbi, Iran, Islamic Republic of
Diesel Exhaust and Vascular Function
- Conditions
- Cardiovascular Effects
- Interventions
- First Posted Date
- 2012-01-12
- Last Posted Date
- 2015-08-03
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 24
- Registration Number
- NCT01508637
- Locations
- 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.